Ano de Publicação: 2010
AUTORIA
Katherine B. D’Antonio1, Lucianna Schultz2, Roula Albadine2, Alison M. Mondul3, Elizabeth
A. Platz1,3,4, George J. Netto1,2,4, and Robert H. Getzenberg1,4
1Brady Urological Institute, Baltimore, Maryland 2Department of Pathology, Johns Hopkins
University School of Medicine, Baltimore, Maryland 3Department of Epidemiology, Johns Hopkins
Bloomberg School of Public Health, Baltimore, Maryland 4Sidney Kimmel Comprehensive Cancer
Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
RESUMO
Purpose—Cysteine-rich angiogenic inducer 61 (Cyr61) is an extracellular matrix protein
involved in the transduction of growth factor and hormone signaling. Previous studies have
suggested that Cyr61 may be a marker for a more aggressive phenotype. In this study, we
evaluated the association between Cyr61 staining intensity and subsequent recurrence after
surgical treatment of clinically localized prostate cancer.
Experimental Design—A study of 229 men with recurrence and 229 controls matched on age,
race, pathologic stage, and Gleason sum nested in a cohort of men who underwent radical
prostatectomy for clinically localized prostate cancer, utilizing immunohistochemistry analysis of
tissue microarray (TMA) sections, was conducted. Odds ratios (OR) of recurrence and 95%
confidence intervals (CIs) were estimated using conditional logistic regression.
Results—Recurrence was identified in 12.2% of cases, and in 24.0% of controls that had at least
1 TMA spot containing cancer with a staining intensity of 3 (P = 0.001). Taking into account age,
pathologic stage and grade, presurgery prostate-specific antigen concentration, and calendar of
surgery as a measure of tissue block storage time, men with a Cyr61 staining intensity of 3 were
56% less likely to recur than men with a lower staining intensity (OR = 0.44, 95% CI = 0.22-0.90).
Conclusions—High Cyr61 staining intensity in adenocarcinoma was associated with a lower
risk of recurrence after surgical treatment of prostate cancer independent of pathologic tumor
characteristics. If validated in other sample sets, Cyr61 may serve as a tissue biomarker for
stratifying men for risk of recurrence and thus could inform treatment decision making.